Stage I | Stage II | Stage III | ||||
---|---|---|---|---|---|---|
Post-surgical radiation | Received BCS | Post-surgical radiation | Received BCS | Post-surgical radiation | Received BCS | |
N (%)2 | N | N (%)2 | N | N (%)2 | N | |
Overall | 3607 (89) | 4067 | 1780 (86) | 2060 | 276 (83) | 331 |
Age at diagnosis | P < 0.001 | P < 0.001 | P < 0.001 | |||
<50 | 821 (93) | 880 | 599 (91) | 656 | 93 (83) | 112 |
50-59 | 1096 (94) | 1171 | 521 (89) | 585 | 94 (93) | 101 |
60-69 | 971 (92) | 1051 | 392 (91) | 430 | 57 (86) | 66 |
70-79 | 601 (86) | 697 | 211 (85) | 248 | 23 (85) | 27 |
≥80 | 118 (44) | 268 | 57 (40) | 141 | 9 (36) | 25 |
Geography of surgery | P < 0.001 | P = 0.001 | P = 0.70 | |||
Calgary | 1485 (91) | 1637 | 783 (87) | 901 | 113 (81) | 139 |
South | 236 (82) | 289 | 113 (78) | 145 | 20 (80) | 25 |
Central | 149 (84) | 178 | 90 (80) | 112 | 14 (82) | 17 |
Edmonton | 1640 (89) | 1849 | 738 (89) | 832 | 114 (85) | 134 |
North | 97 (85) | 114 | 56 (80) | 70 | 15 (94) | 16 |
Year of diagnosis | P = 0.06 | P = 0.01 | P = 0.10 | |||
2002 - 2004 | 1148 (90) | 1277 | 565 (89) | 632 | 78 (91) | 86 |
2005 - 2007 | 1145 (87) | 1315 | 560 (84) | 668 | 101 (81) | 124 |
2008 - 2010 | 1314 (89) | 1475 | 655 (86) | 760 | 97 (80) | 121 |
ER/PR Status & Hormone therapy | P < 0.001 | P < 0.001 | P < 0.001 | |||
ER/PR positive & received hormone | 2337 (93) | 2514 | 1399 (92) | 1516 | 213 (90) | 237 |
ER/PR positive & no hormone | 685 (77) | 893 | 79 (46) | 170 | 7 (24) | 29 |
ER/PR negative | 585 (89) | 660 | 302 (81) | 374 | 56 (86) | 65 |
Neo-adjuvant chemotherapy | P = 0.57 | P = 0.36 | P = 0.10 | |||
Not received | 3601 (89) | 4060 | 1720 (86) | 1994 | 256 (84) | 303 |
Received | 6 (86) | 7 | 60 (91) | 66 | 20 (71) | 28 |
Adjuvant chemotherapy | P < 0.001 | P < 0.001 | P < 0.001 | |||
Not received | 2951 (87) | 3381 | 617 (75) | 823 | 52 (55) | 95 |
Received | 656 (96) | 686 | 1163 (94) | 1237 | 224 (95) | 236 |